Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

In her interview with Easton Jr. on Saturday, Torres shared her thoughts on the GSK’s THRIVE@50+ campaign ... memorable cast reunion alongside Judge Judy for the Super Bowl LVIII commercial during ...

As the company faces criticism for its decision last year to not renew insurance policies for 72,000 property owners in California, State Farm has nixed plans to run a commercial during this year ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

GSK started this year’s J.P. Morgan Healthcare ... adding that IDRx has all the characteristics he and Chief Commercial Officer Luke Miels look for in business deals. “It's got an interesting ...